There are currently 77 active clinical trials seeking participants for Ulcerative Colitis research studies. The states with the highest number of trials for Autism participants are Florida, California, Texas and New York.
Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis
NCT06311123
Recruiting
The goal of this observational study is to learn about the mechanism of action of ozanimod in patients with ulcerative colitis (UC). The main questions it aims to answer are: Prospectively assess the effects of ozanimod on the cellular composition of intestinal lamina propria and blood by deep immunophenotyping (CyTOF) of immune cell subsets prior and after the drug's administration. Determine whether changes in cell subsets observed via mass cytometry correlate with with clinical or histologic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: University of California San Diego, San Diego, California
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic Moderate
Register for Updates
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567
Recruiting
The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
Gender:
All
Ages:
2 years and above
Trial Updated:
03/05/2024
Locations: Phoenix Childrens Hospital -1919 E Thompson Rd, Phoenix, Arizona +67 locations
Conditions: Ulcerative Colitis, Crohn's Disease
Register for Updates
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230
Recruiting
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU, patients having had inadequate response or intolerance to oral or IV corticosteroids or azathioprine or 6-mercaptopurine or TNFi will be enrolled. All eligible participants will initially receive open label tofacitinib... Read More
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
03/04/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona +97 locations
Conditions: Ulcerative Colitis
Register for Updates
Nicotinamide Riboside in Ulcerative Colitis
NCT05561738
Recruiting
This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).
Gender:
All
Ages:
18 years and below
Trial Updated:
03/02/2024
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Ulcerative Colitis
Register for Updates
The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis
NCT05180279
Recruiting
The purpose of this study is to investigate if circadian malalignment (unusual sleeping patterns), such as night shifts (sleeping during the day and being awake during the night time), worsens the inflammation of the gut. We hope to look at patients with Ulcerative Colitis and Healthy Controls.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
02/29/2024
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Ulcerative Colitis
Register for Updates
Fecal Microbiome Transplant
NCT02636517
Recruiting
Fecal Microbiota Transplant (FMT) in pediatric patients with recurrent C. Difficile with or without Inflammatory Bowel Disease (IBD) The aims of this study are to determine the safety and efficacy of FMT treatment in pediatric patients with recurrent or moderate to severe C. Difficile without (through an observational study) and with (through a clinical trial) Inflammatory Bowel Disease and to determine the effect of FMT on the gut microbiota through the use of 454 pyrosequencing before and aft... Read More
Gender:
All
Ages:
Between 3 years and 21 years
Trial Updated:
02/13/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Clostridium Difficile, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Register for Updates
Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis
NCT05176366
Recruiting
Protocol Summary Title: A Phase I study of ExoFlo, an ex vivo culture-expanded adult allogeneic bone marrow mesenchymal stem cell derived extracellular vesicle isolate product, for the treatment of medically refractory ulcerative colitis. Short Title: ExoFlo for ulcerative colitis Phase: 1 Methodology: Open label Study Duration: 24 months Subject Participation: 58 weeks Single or Multi-Site: Multi-Site
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/09/2024
Locations: Direct Biologics Investigational Site, Los Angeles, California +1 locations
Conditions: Ulcerative Colitis, Inflammatory Bowel Diseases
Register for Updates
Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
NCT04626947
Recruiting
The study will compare the effectiveness of Bezlotoxumab in individuals with active C. diff ( Clostridium difficile) infection who are diagnosed with Inflammatory Bowel Disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections
Register for Updates
Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)
NCT03669822
Recruiting
Ulcerative colitis (UC) is a chronic, progressive immunologically mediated disease affecting nearly 1 million Americans. Up to one third of patients with UC will require hospitalization for severe disease (termed 'acute severe colitis (ASUC)'), often within the first year after diagnosis. Investigators will develop a large multi-center cohort of patients with ASUC with homogeneously collected detailed longitudinal clinical and laboratory data.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2024
Locations: Joanna Melia, Baltimore, Maryland
Conditions: Ulcerative Colitis
Register for Updates
Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis
NCT05213234
Recruiting
The hypothesis of this study is that appropriate time of day of administration of oral, once daily 5-ASA therapy in alignment with the host circadian rhythms will improve subclinical inflammation and microbial structure/function and increase mucosal 5-ASA levels. All subjects will be randomized to once daily 5-ASA medications at two different times of the day: between 06:00 - 10:00 h or 18:00 - 22:00 h. Three disease assessments will performed at: 1) enrollment just before randomization; 2) mon... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/26/2024
Locations: Rush University Medical Center, Chicago, Illinois +1 locations
Conditions: Ulcerative Colitis
Register for Updates
CP101 for the Treatment of Ulcerative Colitis
NCT05852574
Recruiting
This is a dose ranging exploratory phase 1 pilot study to assess engraftment, safety, and efficacy of CP101, an oral microbiome therapeutic, in participants with active mild-to-moderate Ulcerative colitis. A total of 30 patients who meet eligibility criteria will be randomized 1:1 to either a short or extended induction dosing with CP101. An assessment of the microbiome will occur at baseline, Day 6, Week 4, Week 8, Week 12, Week 16, and Week 24.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/25/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Ulcerative Colitis
Register for Updates
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
NCT04767984
Recruiting
This phase II trial studies the effect of atorvastatin in treating patients with ulcerative colitis who have a dominant-negative missense P53 mutation and are at risk of developing large intestinal cancer. Patients with ulcerative colitis are known to have an increased risk of developing large intestinal cancer. Better ways to control ulcerative colitis and more knowledge about how to prevent colon cancer are needed. Atorvastatin is a drug used to lower the amount of cholesterol in the blood and... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
01/23/2024
Locations: Northwestern University, Chicago, Illinois +2 locations
Conditions: Ulcerative Colitis, Colorectal Carcinoma
Register for Updates